biosytech
MEDICAL LABORATORY

BML534616

# Laboratory Investigation Report

| | | | | | |
|---|---|---|---|---|---|
| **Name** | : | Ms. ANISHA ANIL KATTIKKARAN | **Ref No.** | : | 44724 |
| **DOB** | : | 29/09/1999 | **Sample No.** | : | 2503547732 |
| **Age / Gender** | : | 25 Y / Female | **Collected** | : | 06/03/2025 19:30 |
| **Referred by** | : | Dr. AMAIZAH | **Registered** | : | 06/03/2025 22:19 |
| **Centre** | : | CITICARE MEDICAL CENTER | **Reported** | : | 06/03/2025 23:40 |

## BIOCHEMISTRY

| Test | Result | Flag | Unit | Reference Range | Methodology |
|---|---|---|---|---|---|
| **C-REACTIVE PROTEIN (CRP)** | 1.2 | | mg/L | < 5.0<br>Please note change.<br>Source: Roche IFU. | Particle-enhanced immunoturbidimetric assay |

**INTERPRETATION NOTES :**

1. CRP measurements are used as aid in diagnosis, monitoring, prognosis, and management of suspected inflammatory disorders and associated diseases, acute infections and tissue injury.
2. C-reactive protein is the classic acute phase protein in inflammatory reactions.
3. CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. The CRP response frequently precedes clinical symptoms, including fever. After onset of an acute phase response, the serum CRP concentration rises rapidly and extensively. The increase begins within 6 to 12 hours and the peak value is reached within 24 to 48 hours. Levels above 100 mg/L are associated with severe stimuli such as major trauma and severe infection (sepsis).
4. CRP response may be less pronounced in patients suffering from liver disease.
5. CRP assays are used to detect systemic inflammatory processes (apart from certain types of inflammation such as systemic lupus erythematosus (SLE) and Colitis ulcerosa); to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from SLE or Colitis ulcerosa; to therapeutically monitor rheumatic disease and assess anti-inflammatory therapy; to determine the presence of post-operative complications at an early stage, such as infected wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow transplant rejection.

*Sample Type :* Serum

*End of Report*

**Dr. Adley Mark Fernandes**
**M.D (Pathology)**
**Pathologist**

**Dr. Vyoma V Shah**
**M.D (Pathology)**
**Clinical Pathologist**

**MOHAMMED RASHID CHENANGADATH**
Laboratory Technologist

This is an electronically authenticated report



Printed on: 06/03/2025 23:42

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

P.O Box: 49527 Dubai, UAE Tel: +971 4 398 8567 reports@biosytech.ae www.biosytech.com

biosytech
MEDICAL LABORATORY

BML534616

# Laboratory Investigation Report

| | | | | | |
|---|---|---|---|---|---|
| **Name** | : | Ms. ANISHA ANIL KATTIKKARAN | **Ref No.** | : | 44724 |
| **DOB** | : | 29/09/1999 | **Sample No.** | : | 2503547732 |
| **Age / Gender** | : | 25 Y / Female | **Collected** | : | 06/03/2025 19:30 |
| **Referred by** | : | Dr. AMAIZAH | **Registered** | : | 06/03/2025 22:19 |
| **Centre** | : | CITICARE MEDICAL CENTER | **Reported** | : | 06/03/2025 23:10 |

## HEMATOLOGY

| Test | Result | Flag | Unit | Reference Range | Methodology |
|---|---|---|---|---|---|
| **COMPLETE BLOOD COUNT (CBC)** | | | | | |
| **HEMOGLOBIN** | 12.8 | | g/dL | 12 - 15.5 | Photometric |
| **RBC COUNT** | 4.4 | | 10^6/µL | 3.9 - 5 | Electrical Impedance |
| **HEMATOCRIT** | 38.2 | | % | 35 - 45 | Calculation |
| **MCV** | 86.1 | | fL | 82 - 98 | Calculation |
| **MCH** | 28.9 | | pg | 27 - 32 | Calculation |
| **MCHC** | 33.6 | | g/dL | 32 - 37 | Calculation |
| **RDW** | 13.5 | | % | 11.9 - 15.5 | Calculation |
| **RDW-SD** | 41.6 | | fL | | Calculation |
| **MPV** | 7.9 | | fL | 7.6 - 10.8 | Calculation |
| **PLATELET COUNT** | 347 | | 10^3/uL | 150 - 450 | Electrical Impedance |
| **PCT** | 0.3 | | % | 0.01 - 9.99 | Calculation |
| **PDW** | 16.4 | | Not Applicable | 0.1 - 99.9 | Calculation |
| **NUCLEATED RBC (NRBC)^** | 0 | | /100 WBC | | VCS 360 Technology |
| **ABSOLUTE NRBC COUNT^** | 0 | | 10^3/uL | | Calculation |
| **EARLY GRANULOCYTE COUNT (EGC)^** | 0.2 | | % | | VCS 360 Technology |
| **ABSOLUTE EGC^** | 0 | | 10^3/uL | | Calculation |
| **WBC COUNT** | 9.2 | | 10^3/µL | 4 - 11 | Electrical Impedance |
| **DIFFERENTIAL COUNT (DC)** | | | | | |
| NEUTROPHILS | 62 | | % | 40 - 75 | VCS 360 Technology |
| LYMPHOCYTES | 30 | | % | 30 - 60 | VCS 360 Technology |
| EOSINOPHILS | 2 | | % | 0 - 6 | VCS 360 Technology |
| MONOCYTES | 6 | | % | 1 - 6 | VCS 360 Technology |
| BASOPHILS | 0 | | % | 0 - 1 | VCS 360 Technology |
| **ABSOLUTE COUNT** | | | | | |
| ABSOLUTE NEUTROPHIL COUNT | 5.7 | | 10^3/uL | 1.6 - 8.25 | Calculation |
| ABSOLUTE LYMPHOCYTE COUNT | 2.5 | | 10^3/uL | 1.2 - 6.6 | Calculation |
| ABSOLUTE MONOCYTE COUNT | 0.5 | | 10^3/uL | 0.04 - 0.66 | Calculation |
| ABSOLUTE EOSINOPHIL COUNT | 0.2 | | 10^3/uL | 0 - 0.66 | Calculation |
| ABSOLUTE BASOPHIL COUNT | 0.0 | | 10^3/uL | 0 - 0.11 | Calculation |

**Dr. Adley Mark Fernandes**
**M.D (Pathology)**
**Pathologist**

**Dr. Vyoma V Shah**
**M.D (Pathology)**
**Clinical Pathologist**

**Reena Babu**
Laboratory Technologist

This is an electronically authenticated report



Printed on: 06/03/2025 23:42

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

P.O Box: 49527 Dubai, UAE Tel: +971 4 398 8567 reports@biosytech.ae www.biosytech.com

biosytech
MEDICAL LABORATORY

BML534616

# Laboratory Investigation Report

| | | | | | |
|---|---|---|---|---|---|
| **Name** | : | Ms. ANISHA ANIL KATTIKKARAN | **Ref No.** | : | 44724 |
| **DOB** | : | 29/09/1999 | **Sample No.** | : | 2503547732 |
| **Age / Gender** | : | 25 Y / Female | **Collected** | : | 06/03/2025 19:30 |
| **Referred by** | : | Dr. AMAIZAH | **Registered** | : | 06/03/2025 22:19 |
| **Centre** | : | CITICARE MEDICAL CENTER | **Reported** | : | 06/03/2025 23:10 |

## HEMATOLOGY

| Test | Result | Flag | Unit | Reference Range | Methodology |
|---|---|---|---|---|---|
| **COMPLETE BLOOD COUNT (CBC)** | | | | | |

INTERPRETATION NOTES :

Please note update on CBC report format, reference ranges and method(Beckman Coulter).

*Sample Type :* *EDTA Whole Blood*

*End of Report*

**Dr. Adley Mark Fernandes**
**M.D (Pathology)**
**Pathologist**

**Dr. Vyoma V Shah**
**M.D (Pathology)**
**Clinical Pathologist**

**Reena Babu**
Laboratory Technologist

This is an electronically authenticated report



Printed on: 06/03/2025 23:42

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

P.O Box: 49527 Dubai, UAE Tel: +971 4 398 8567 reports@biosytech.ae www.biosytech.com

biosytech
MEDICAL LABORATORY

BML534616

# Laboratory Investigation Report

| | | | | | |
|---|---|---|---|---|---|
| **Name** | : | Ms. ANISHA ANIL KATTIKKARAN | **Ref No.** | : | 44724 |
| **DOB** | : | 29/09/1999 | **Sample No.** | : | 2503547732 |
| **Age / Gender** | : | 25 Y / Female | **Collected** | : | 06/03/2025 19:30 |
| **Referred by** | : | Dr. AMAIZAH | **Registered** | : | 06/03/2025 22:19 |
| **Centre** | : | CITICARE MEDICAL CENTER | **Reported** | : | 06/03/2025 23:40 |

## IMMUNOLOGY

| Test | Result | Flag | Unit | Reference Range | Methodology |
|---|---|---|---|---|---|
| **IGE TOTAL ANTIBODY** | **1248** | **H** | IU/mL | Refer to Table below in interpretation notes | ECLIA |

**INTERPRETATION NOTES :**

**Age – wise Reference Range:**

| Age group | IU/mL |
|---|---|
| Neonates | <1.5 |
| Infants in 1st year of life | <15 |
| Children aged 1 - 5 years | <60 |
| Children aged 6 - 9 years | <90 |
| Children aged 10 - 15 years | <200 |
| Adults | <100 |
| *Please note change in reference range (Source: Roche)* | |

1. Immunoglobulin E (IgE) is a type of antibody synthesized by plasma cells
2. IgE plays an important role in immunological protection against parasitic infections and in allergy (type 1 hypersensitivity).
3. The IgE concentration in serum is normally very low as IgE is the least abundant antibody in serum (0.05 % of the IgG concentration). The IgE concentration is age-dependent, with the lowest values being measured at birth. Its concentration gradually increases and becomes stabilized between the age of 5-7, although the IgE values vary greatly within particular age groups.
4. Elevated IgE concentrations are seen in patients with Type 1 hypersensitivity reactions such as Anaphylactic reactions (reaction to drugs, bee stings, latex, vaccines, or antigen preparation used in desensitization immunotherapy), allergic diseases such as hay fever, atopic bronchitis, asthma, food allergies, urticaria and dermatitis.
5. Increased IgE concentrations can also occur in non-allergic diseases, e.g. congenital immunodeficiency syndromes, HIV infection, graft-versus- host disease, severe burns, some inflammatory diseases, certain cancers and parasitic diseases.
6. Low IgE levels may be seen in auto-immune disorders.

**Note:** Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

**References:**


1. Kit Insert
2. Dati F, Ringel KP. Reference values for serum IgE in healthy non- atopic children and adults. Clin Chem 1982;28(7):1556.
3. Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, et al. (2003). "The biology of IGE and the basis of allergic disease". Annual Review of Immunology. 21: 579–628


*Sample Type :* Serum

*End of Report*

**Dr. Adley Mark Fernandes**
**M.D (Pathology)**
**Pathologist**

**Dr. Vyoma V Shah**
**M.D (Pathology)**
**Clinical Pathologist**

**MOHAMMED RASHID CHENANGADATH**
Laboratory Technologist

This is an electronically authenticated report



Printed on: 06/03/2025 23:42

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

P.O Box: 49527 Dubai, UAE Tel: +971 4 398 8567 reports@biosytech.ae www.biosytech.com